ClinicalTrials.gg
Active, not recruitingNCT07941427INFLUENCEUpdated Nov 17, 2026

Increasing Flu Vaccination Through Evidence-Based Nudges

An interventional study of Gain framing email and Loss framing email in Influenza, Vaccination Coverage and Healthcare Worker, sponsored by Istituto Clinico Humanitas. Active, not recruiting at 17 sites in Italy. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Istituto Clinico Humanitas · Not applicable, Interventional, and Prevention

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
45,000
Allocation
Randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 52 studies in Influenza, Human with a site in Italy — 3 open to participants now, 4 under way, 2 of them phase 3. Influenza, Human · Italy.

Planned enrollment
Largest of 44
45,000 · median 136
Started
2026
the only one that year
No phase
Only one
of the 52
Registered
52nd of 52
by date

Among the 52 studies in Influenza, Human with a site in Italy, this one has the largest planned enrollment of the 44 interventional ones that give a count, is the only one that started in 2026, is the only one with no phase, and was the 52nd registered.

Influenza, Human

2,360 studies on the registry are indexed under Influenza, Human; 185 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

3 of the 52 studies in Influenza, Human with a site in Italy are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 123 Influenza, Human studies recruiting now, 66 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 68 take healthy volunteers.

This study: all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 52 studies in Influenza, Human with a site in Italy, or all of them as a file.
02

Study summary

This study aims to find out whether changing the wording and content of workplace emails can encourage more healthcare and non-healthcare staff to get a seasonal flu vaccine. The main question is whether emails that highlight the benefits of vaccination, the possible consequences of not getting vaccinated, or vaccination rates among colleagues are more effective than standard information emails.

The study will take place during the 2026-2027 flu vaccination campaign across 17 healthcare and social care organizations in Lombardy, Italy. Approximately 45,000 eligible workers are expected to be included, covering both staff who provide patient care and those in administrative, technical, and support roles.

Workplace groups, such as departments or organizational units, are randomly assigned to one of four email communication approaches:

  • Standard information (control): emails communicating that the vaccination campaign is ongoing and that it is possible to get vaccinated.
  • Benefits of vaccination (gain framing): emails emphasizing the potential benefits of vaccination for workers, patients, colleagues, and the organization.
  • Consequences of not getting vaccinated (loss framing): emails emphasizing the possible risks and negative consequences for workers, patients, colleagues, and the organization.
  • Vaccination among colleagues (social norms): emails and follow-up updates showing vaccination progress and, where possible, comparing vaccination rates in the recipient's workplace group with those in other groups.

Researchers will use existing vaccination and employment records to compare the percentage of workers who receive a flu vaccine in each group by the end of the campaign. They will also examine whether the emails encourage earlier vaccination and whether their effects differ across workplaces and staff groups. Where suitable records are available, they will explore differences in sickness absence during the campaign.

Vaccination will remain voluntary, and all workers will continue to have access to the usual vaccination services. The study involves workplace emails and the use of existing records; no additional medical visits, tests, or procedures are required.

The findings will help healthcare organizations decide whether simple changes to routine communication can improve staff flu vaccination rates and which approach works best.

Read the detailed description

Seasonal influenza represents a major public health issue, associated with morbidity, mortality, pressure on healthcare services, workforce absenteeism and risk of transmission in care settings. Influenza vaccination of healthcare and non-healthcare workers employed in healthcare and social care organisations is an important preventive measure, not only for individual protection, but also for the indirect protection of frail patients, reduction of transmission in healthcare settings, preservation of continuity of care and resilience of healthcare services. Despite the availability of influenza vaccination and public health recommendations, vaccination uptake among healthcare and non-healthcare workers remains suboptimal and variable across organisations, professional profiles and organisational units. Communication strategies informed by behavioural science, commonly referred to as "nudges", represent low-cost, scalable organisational interventions that may guide individuals towards preventive behaviours while preserving individual autonomy. The study aims to evaluate the effectiveness of an organisational and behavioural communication strategy with potential impact on prevention, quality of care pathways, workforce resilience and public health.

Primary objective: to evaluate the effectiveness of nudge-based communication strategies, assigned at organisational cluster level, in increasing influenza vaccination uptake among eligible healthcare and non-healthcare workers during the 2026-2027 influenza vaccination campaign compared with standard institutional communication.

Secondary objectives:

  • to compare the relative effectiveness of the different communication arms, including standard communication, gain framing, loss framing and social norms/peer feedback;
  • to assess the change in influenza vaccination uptake during the 2026-2027 campaign compared with the 2025-2026 campaign, where historical data are available; to evaluate time to vaccination;
  • to explore heterogeneity of effect by organisational cluster, healthcare/non-healthcare area and previous vaccination history, where available;
  • to assess sickness absence indicators at cluster level during the vaccination campaign, where such data are available and comparable across participating organisations;
  • to generate evidence to inform future organisational, regional and potentially national vaccination communication and prevention policies.

Primary endpoint:

Influenza vaccination uptake during the 2026-2027 influenza vaccination campaign, defined as the proportion of eligible healthcare and non-healthcare workers within the randomised clusters who receive influenza vaccination by the end of the observation period. Documented vaccinations will be considered irrespective of the setting in which they are administered, including vaccinations administered within the participating organisation or through other authorised vaccination pathways, where captured by ARVAX or other applicable regional administrative data sources.

Secondary endpoints:

  • Absolute percentage-point change in influenza vaccination uptake between the 2026-2027 campaign and the 2025-2026 campaign, at cluster level;
  • Time to vaccination, defined as the number of days between delivery of the communication assigned to the cluster and the documented date of influenza vaccination;
  • Sickness absence indicators at cluster level during the vaccination campaign, including number of sickness absence days and/or sickness absence rates standardised by eligible population or person-time, according to data availability and quality.

Population and patient selection criteria: The study population consists of healthcare and non-healthcare workers eligible for influenza vaccination during the 2026-2027 campaign and belonging to organisational clusters included in the study within the 17 participating Lombardy organisations.

In this protocol, the term "patients/subjects" should be understood as "study participants/workers", since the study is not conducted on assisted patients. Inclusion criteria: employment or affiliation with one of the 17 participating organisations; belonging to an included and randomised organisational cluster; eligibility for influenza vaccination according to applicable regional/organisational recommendations; availability in administrative data flows required to define the denominator; and availability of vaccination outcome data through administrative, regional or organisational data sources.

Exclusion criteria: non-eligibility for influenza vaccination; lack of minimum data required for denominator definition, cluster attribution or outcome ascertainment; belonging to clusters that are not classifiable, mappable or randomizable; termination of employment/affiliation before the start of the campaign if not exposed to the possibility of organisational vaccination; or any other administrative condition preventing correct attribution to cluster, study arm or outcome.

Study design: This is a pragmatic, multicentre, four-arm, parallel-group, cluster-randomised, non-pharmacological procedural-organisational interventional study, prospectively implemented during the 2026-2027 influenza vaccination campaign. Randomisation will occur at the level of organisational clusters, defined as organisational units uniformly identified across participating centres according to FLUPER or another consistent organisational classification available within the participating organisations. Clusters will be allocated in a 1:1:1:1 ratio to one of four arms: standard communication, gain framing, loss framing, and social norms/peer feedback. Outcomes and denominators will be assessed using routinely available administrative, regional and organisational data flows, including FLUPER, the regional healthcare workforce administrative flow used to support workforce denominator definition and organisational classification, and ARVAX, the regional vaccination registry/database used to ascertain vaccination uptake; where available, organisational workforce or human resources data flows used to assess cluster-level sickness absence indicators will be used.

Description of the intervention: The intervention consists of institutional e-mail communications sent by the Vaccination Unit or the competent organisational function of each participating organisation, with content differentiated according to the study arm assigned to the cluster.

  • Arm 1 - Standard communication: standard e-mail containing information on the launch of the influenza vaccination campaign, access procedures, vaccination sites, opening hours and booking channels.
  • Arm 2 - Gain framing: e-mail emphasising the benefits of vaccination for the worker, patients, colleagues and the organisation.
  • Arm 3 - Loss framing: e-mail emphasising the risks and potential negative consequences of non-vaccination for the worker, patients, colleagues and the organisation.
  • Arm 4 - Social norms / peer feedback: periodic e-mails providing updates on campaign progress and, where feasible, comparison between the vaccination uptake rate of the recipient's cluster and that of other clusters or the overall cluster average.

The comparator is standard/informational communication, corresponding to routine communication on the launch of the vaccination campaign and on access procedures.

Number of participants planned: The overall expected number of participants will be determined based on FLUPER/organisational data flows and other available administrative sources from the 17 participating organisations before final randomisation. All eligible healthcare and non-healthcare workers belonging to the randomised clusters are expected to be included.

Total number planned: approximately 45,000 healthcare and non-healthcare workers across all 17 participating organisations, subject to confirmation based on the final eligible workforce denominator derived from FLUPER and/or organisational administrative data flows before randomisation. Number planned per arm: approximately one quarter of the overall eligible population, depending on the number and size of randomised cluster

03

Conditions studied

  • Influenza
  • Vaccination Coverage
  • Healthcare Worker

Browse trials for

Keywords

  • Vaccination
  • influenza
  • flu
  • healthcare workers
  • nudge
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • employment or affiliation with one of the 17 participating organisations;
  • belonging to an included and randomised organisational cluster;
  • availability in administrative data flows required to define the denominator;
  • availability of vaccination outcome data through administrative regional data sources.

Exclusion criteria

Exclusion criteria:

  • lack of minimum data required for denominator definition, cluster attribution or outcome ascertainment;
  • belonging to clusters that are not classifiable, mappable or randomizable.
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
45,000 participants (estimated)

Study arms

  • Active comparator
    Control

    Standard communication: standard e-mail informing that the vaccination campaing is ongoing and inviting healthcare workers to participate.

    Behavioral: Control email

  • Experimental
    Gain Framing

    Gain framing: e-mail emphasising the benefits of vaccination for the worker, patients, colleagues and the organisation.

    Behavioral: Gain framing email

  • Experimental
    Loss framing

    Loss framing: e-mail emphasising the risks and potential negative consequences of non-vaccination for the worker, patients, colleagues and the organisation.

    Behavioral: Loss framing email

  • Experimental
    Social norms

    Social norms: weekly e-mails providing updates on campaign progress and comparison between the vaccination uptake rate of the recipient's cluster and that of other clusters assigned to the same experimental arm.

    Behavioral: Social norms email

Interventions

  • BehavioralGain framing email

    Dear Colleague, The seasonal flu vaccination campaign is underway. Flu is not always a mild illness. Globally, it is estimated to cause 3-5 million cases of severe illness and 290,000-650,000 deaths associated with respiratory disease each year. In Italy, more than 21,000 hospital admissions each year are attributable to flu or related respiratory and cardiovascular complications. Getting vaccinated against flu protects both individual and community health: * It reduces the spread of the flu virus, benefiting care recipients, patients, colleagues, and family members. * It reduces the risk of complications in people with chronic conditions. * It reduces the risk of a heart attack in the seven days following a confirmed flu infection. If you have not yet been vaccinated, please remember that you can receive your vaccination by following the instructions previously provided. Thank you for your attention and for contributing to this prevention effort.

  • BehavioralLoss framing email

    Dear Colleague, The seasonal flu vaccination campaign is underway. Flu is not always a mild illness. Globally, it is estimated to cause 3-5 million cases of severe illness and 290,000-650,000 deaths associated with respiratory disease each year. In Italy, more than 21,000 hospital admissions each year are attributable to flu or related respiratory and cardiovascular complications. Not getting vaccinated against flu increases both individual and community risks: * It increases the spread of the flu virus, affecting care recipients, patients, colleagues, and family members. * It increases the risk of complications in people with chronic conditions. * It increases the risk of a heart attack in the seven days following a confirmed flu infection. If you have not yet been vaccinated, please remember that you can receive your vaccination by following the instructions previously provided. Thank you for your attention and for contributing to this prevention effort.

  • BehavioralSocial norms email

    Dear Colleague, The seasonal flu vaccination campaign is underway. To encourage staff vaccination, the Agency will send a brief weekly update on the campaign's progress from now through December. These updates will compare vaccination rates across selected organizational units within the Agency. The units were selected at random and were formed by grouping organizational structures with similar areas of activity. If you have not yet been vaccinated, please remember that you can receive your vaccination by following the instructions previously provided. Thank you for your attention and for contributing to this prevention effort.

  • BehavioralControl email

    Dear Colleague, The seasonal flu vaccination campaign is underway. If you have not yet been vaccinated, please remember that you can receive your vaccination by following the instructions previously provided. Thank you for your attention and for contributing to this prevention effort.

06

What researchers measure

Primary outcomes

  1. Influenza vaccination uptake at the end of 2026-2027 campaign.

    Proportion of eligible healthcare and non-healthcare workers within the randomised clusters who receive influenza vaccination by the end of the observation period of the campaign.

    Time frame: Up to 6 months

Secondary outcomes

  1. Influenza vaccination uptake at mid 2026-2027 campaign.

    Proportion of eligible healthcare and non-healthcare workers within the randomised clusters who receive influenza vaccination at mid of the campaign.

    Time frame: Up to 3 months

  2. Change in influenza vaccination uptake between seasons.

    Absolute percentage-point change in influenza vaccination uptake between the 2026-2027 campaign and the 2025-2026 campaign.

    Time frame: Baseline and 6 months

  3. Time to vaccination.

    The number of days between the delivery of the communication assigned to the cluster and the documented date of influenza vaccination.

    Time frame: Up to 6 months

  4. Sickness absence.

    Number of sickness absence days and/or sickness absence rates standardised by eligible population or person-time.

    Time frame: Up to 6 months

07

Study locations

17 sites
08

References and documents

Individual participant data

Plan to share: No — No IPD data will be collected as part of the study.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Mar 2027, 5 months after the start.

Of 147 non-industry interventional studies with no phase under Influenza, Human, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 18. This study's planned 5 months is below that.

Counting every sponsor, half of 167 studies reached it within 6 months; a quarter within 3 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 30, 2026
First posted
Nov 17, 2026
StartActual
Oct 21, 2026
Primary completionEst.
Mar 31, 2027
CompletionEst.
Mar 31, 2027
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07941427
Responsible party
Elena Azzolini (Professor, Istituto Clinico Humanitas) — Principal investigator
First posted
Nov 17, 2026
Start date
Oct 21, 2026
Primary completion
Mar 31, 2027 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
Nov 17, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion